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Abstract It is known that the HER2/neu proto-oncogene is
associated with a wide variety of human cancers and considered
to be an attractive target for developing anti-cancer agents. We
report here for the ¢rst time that the Epstein^Barr virus nuclear
antigen-1 (EBNA1) suppresses the HER2/neu oncogene expres-
sion at the transcriptional level. Recombinant clones of EBNA1
were subcloned and stably transfected into HER2/neu-over-
expressing human ovarian cancer SKOV3.ip1 cells. These
EBNA1-containing clones down-regulated the endogenous pro-
duction of p185HER2=neu. In addition, the EBNA1-expressing
stable transfectants showed reduced growth rate, low soft aga-
rose colony-forming ability and tumorigenic potential as com-
pared with the parental line. These data suggest that EBNA1
may act as a transforming suppressor of the HER2/neu onco-
gene.
0 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The loss of control in the genetic regulation of the HER2/
neu (also known as c-erbB-2) proto-oncogene is associated
with many types of human cancers. The progress of malig-
nancy and metastasis due to HER2/neu overexpression has
been demonstrated both in vitro and in vivo. The malignant
phenotypes of HER2/neu-overexpressing cancer cells can be
repressed by targeting HER2/neu, which suggests that
HER2/neu itself is a good target for developing cancer gene
therapy (reviewed in [1,2]). Therefore, down-regulation of
HER2/neu oncogene expression may be an e¡ective approach
to the treatment of the HER2/neu-overexpressing human can-
cers [3,4].
Many HER2/neu oncogene suppressors have been reported,
including p53, Rb, SV40 large T antigen, E1A, c-Myc, c-Myb,
c-Cbl, and PEA3 gene product [5^13]. During research on the
transcriptional suppression of the neu promoter by the N-ter-
minal domain of the SV40 large T antigen [8], we discovered
that the EBNA1-containing plasmid vector pCEP4 alone was
able to signi¢cantly repress the neu promoter activity in a
transient transfection assay. In this paper, we further charac-
terized this newly discovered HER2/neu oncogene suppressor,
that is, the Epstein^Barr virus nuclear antigen-1 (EBNA1).
EBNA1, the major nuclear antigen of the oncogenic human
herpes virus, Epstein^Barr virus (EBV) [14], is a multifunc-
tional phosphoprotein of 641 amino acid residues [15]. It is
the only viral protein consistently expressed in all EBV-in-
fected cells and is necessary for replication and the mainte-
nance of the EBV extrachromosomal episomes of the latent
form of EBV [16,17]. These functions result from the speci¢c
binding of EBNA1 to DNA at the oriP site of the EBV ge-
nome [17,18]. EBNA1 plays an important role in the dereg-
ulation of cellular proliferation [19,20]. In the present paper,
to further elucidate the mechanism for suppression of HER2/
neu-mediated transformation by EBNA1 and explore its clin-
ical applications in human cancer gene therapy, we established
a construct with the EBNA1 coding region that can e¡ectively
repress the HER2/neu gene function in vitro and in vivo.
These results suggest that EBNA1 gene therapy aimed at
down-regulation of HER2/neu may provide a new useful ap-
proach in the treatment of HER2/neu-overexpressing ovarian
cancer.
2. Materials and methods
2.1. Plasmids and bacterial strains
The pNeuEcoRVCAT plasmid, in which a DNA segment contain-
ing the neu promoter was fused with the CAT reporter [21], was used
in all the CAT assays. pCMVL, a plasmid containing the bacterial
L-galactosidase gene under the control of the cytomegalovirus (CMV)
long terminal repeat, was used to monitor transfection e⁄ciency.
Plasmid pcDNA3 (Invitrogen) was an expression vector containing
the CMV promoter and the neomycin-selection marker. pCEP4 was
a plasmid which contained the EBNA1 gene and an ampicillin-resis-
tance gene marker. pRSVCAT was a plasmid which contained the
Rous sarcoma virus (RSV) promoter-driven CAT reporter and an
ampicillin-resistance gene marker. All plasmids were ampli¢ed in Es-
cherichia coli DH5K and puri¢ed using a Wizard Maxipreps Kit
(Promega, Madison, WI, USA).
2.2. Construction of plasmids containing wild-type and mutant EBNA1
genes
A frame-shift mutant of EBNA1 was generated by cutting the
pCEP4 plasmid DNA sequence with AvrII. This was followed by a
T4 DNA polymerase ¢lling-in reaction and blunt-end ligation (insert-
ing four bases at the cutting site) to form pCEP4-AvrII. The mutant
pcDNA3-EBNA1-AvrII was constructed in the same way. The 2.2-kb
wild-type EBNA1 gene was cut out of the plasmid pCEP4 with StuI
and MscI and subcloned into the EcoRV site of the plasmid vector
pcDNA3 to form pcDNA3-EBNA1. All recombinant clones were
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veri¢ed by sequence analysis using a Sequenase V2.0 Kit (USB-Amer-
sham).
2.3. Cell lines, culture and transfection
The SKOV3.ip1 human ovarian carcinoma cell line was established
from ascites that developed in a nu/nu mouse injected i.p. with SKOV3
cells. NIH3T3 and SKOV3.ip1 cells were grown in a 1:1 mixture of
Dulbecco’s modi¢ed Eagle’s medium (DMEM)/F12 medium supple-
mented with 10% fetal bovine serum (FBS, Gibco-BRL, Grand Is-
land, NY, USA). The cells were incubated at 37‡C in a humidi¢ed, 5%
CO2 atmosphere. NIH3T3 cells were used as the recipient cells for all
DNA constructs in all transient transfection experiments. The calcium
phosphate precipitation method was used for transient transfection
[22]. Brie£y, 5U105 cells were plated in a 100-mm-diameter tissue
culture dish overnight; 10 Wg of recombinant EBNA1 or its mutant,
10 Wg of pNeuEcoRVCAT and 2 Wg of pCMVL were co-precipitated
and added to the cells. After 20 min at room temperature, the cells
were incubated in 3% CO2 for 12^16 h at 37‡C. The cells then were
washed twice with PBS and fresh medium was added. This was fol-
lowed by incubation in 5% CO2 at 37‡C for 36^48 h.
2.4. CAT assay and L-galactosidase assay
Wild-type and mutant EBNA1-transfected NIH3T3 cells were har-
vested with a cell scraper after transfection. They were washed with
PBS followed by resuspension in 100 Wl of 0.25 M Tris (pH 8). Four
cycles of freeze^thaw^vortex alternating between liquid nitrogen and
37‡C were used to lyse the cells. Cell debris was spun down in a
microfuge, and 100 Wl of cell extract was collected; 10^20 Wl of the
extract was tested for L-galactosidase activity [23] to monitor trans-
fection e⁄ciency. Cell extracts were added to a reaction bu¡er con-
taining 650 Wl of 0.1 M phosphate bu¡er (pH 7.3), 50 Wl of 30 mM
MgCl2, and 50 Wl of 3.34 M L-mercaptoethanol. Then, 750 Wl of
ONPG (0.13 g/100 ml phosphate bu¡er) was added, and the reaction
mixture was incubated at 37‡C until a yellow color was observed. The
reaction was stopped with 500 Wl of 1 M Na2CO3, and the optical
density at a wavelength of 410 nm was measured. Normalized quan-
tities of cell extracts were then used for the CAT assay [24]. The cell
extract was heated to 60‡C for 10 min and then added to the CAT
reaction mixture [25]. Reaction time was adjusted according to the
transfection e⁄ciency of each experiment, but was not more than 4 h.
The reaction mixture was extracted with ethyl acetate, dried in a
Speed-Vac, redissolved in ethyl acetate, and separated on a silica gel
thin-layer chromatography (TLC) plate (Whatman). The TLC plate
was then exposed to X-ray ¢lm. The spots corresponding to the posi-
tions of the [14C]chloramphenicol and the acetylated products were
examined by phospho-imager.
2.5. Stable transfection of EBNA1 into SKOV3.ip1 cells
A liposome system was used for delivering the pcDNA3-EBNA1
construct for stable transfection [26]. The stable transfectants were
derived from the parental SKOV3.ip1 cells. The EBNA1-expressing
plasmid pcDNA3-EBNA1 was transfected into the HER2/neu-over-
expressing recipient ovarian cancer line SKOV3.ip1 to generate the
EBNA1-expressing stable transfectants, which were named SKO-
V3.ip1-EBNA1 (ip1-EBNA1-W1 to -W30 and ip1-EBNA1-WL1 to
-WL30). The control lines were generated by transfecting pcDNA3
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Fig. 1. Transcriptional and dose-dependent repression of neu pro-
moter by EBNA1. A: Dose-dependent repression of HER2/neu pro-
moter by pCEP4. A constant amount (10 Wg) of pNeuEcoRVCAT
construct was co-transfected into NIH3T3 cells with either 5 Wg
(lane 2), 10 Wg (lane 3), 20 Wg (lane 4) of pCEP4 DNA or 10 Wg of
the mutant pCEP4-AvrII (lane 5) test construct. The relative CAT
activity without pCEP4 (lane 1) is de¢ned as 100%. B: Transcrip-
tional and dose-dependent repression of HER2/neu promoter by
pcDNA3-EBNA1. A constant amount (10 Wg) of pNeuEcoRVCAT
construct was co-transfected into NIH3T3 cells with increasing
amounts of pcDNA3-EBNA1, which contains the full-length cDNA
of EBNA1. The relative CAT activities with 5 (lane 2), 10 (lane 3)
and 20 Wg (lane 4) of the test constructs and the control EBNA1
frame-shift mutant construct (lane 5) were 90%, 51%, 39% and
115%, respectively. The relative CAT activity without EBNA1 is de-
¢ned as 100% (lane 1). For lanes 6 and 7, NIH3T3 cells were trans-
fected with 10 Wg of the pRSVCAT construct, which contains the
CAT reporter driven by RSV promoter sequences. In lane 6, the
CAT activity of the control transfection with the pRSVCAT plas-
mid is de¢ned as 100%. Lane 7 shows the CAT activity detected
after co-transfection with 10 Wg of pcDNA3-EBNA1 (102%). C: A
bar plot showing the relative CAT activities of panel B. The error
bars indicate the standard deviation of the relative CAT activities,
which were the means of three independent transfections for which
the standard deviation was less than 15%. The total amount of
transfected DNA was kept constant by adding the appropriate
amount of carrier DNA.
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Fig. 2. Stable integration and expression of EBNA1 in SKOV3.ip1 cells resulting in decreased levels of the p185 encoded by HER2/neu. A: Ge-
nomic PCR analysis of DNAs from ip1 and two stable transfectants, ip1-EBNA1-M1 and ip1-EBNA1-W30. The primers used in this experi-
ment were EBNA1-454S and EBNA1-CAS as described in Section 2. Lane 1, pcDNA3-EBNA1 plasmid as the positive control; 2, parental
SKOV3.ip1 as negative control; 3, stable transfectant ip1-M1; 4, ip1-W30. An arrowhead indicates the expected PCR product (578 bp). 100-bp
ladder DNA markers (lane M1) are shown to the right. B: RT-PCR analysis of parental and EBNA1-transfected SKOV3.ip1 cells. Lane 1, pa-
rental SKOV3.ip1 cells; 2, pcDNA3-EBNA1 plasmid as the positive control; 3, ip1-EBNA1-M1 cells; 4, ip1-EBNA1-W30 cells. The primers
used in this experiment were EBNA1-454S and EBNA1-CAS. An arrowhead indicates the expected RT-PCR product (578 bp). M2, 100-bp lad-
der DNA marker. C: Detection of EBNA1 expression in EBNA1-transfected ip1 lines using an indirect immuno£uorescence analysis technique.
The PI staining in the upper row shows the location of the cell nucleus. The lower row shows that EBNA1 is expressed in the nuclei of the
EBNA1-transfected lines, but not in the nuclei of the parental ip1 and mutant ip1-EBNA1-M1 lines. Original magni¢cation was 200U.
D: Western blot analysis of HER2/neu-encoded p185 protein of parental and pcDNA3-EBNA1-transfected SKOV3.ip1 cells. Lane 1, parental
SKOV3.ip1 cells ; 2, vector-only control ip1-EBNA1-C1 cell line; 3, the EBNA1 frame-shift line; 4,5, ip1-EBNA1-WL5 and ip1-EBNA1-W30,
expressing the full-length EBNA1 stable lines. The HER2/neu-encoded p185 protein is shown on the right, and L-actin was used as the protein
loading control.
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vector only (ip1-EBNA1-C1) and pcDNA3-EBNA1-AvrII mutant
(ip1-EBNA1-M1 to -M4) into ip1 cells, respectively. The G418-resis-
tant clones were selected in medium containing 800 Wg of G418 per ml
for 4^6 weeks and expanded to cell lines.
2.6. Genomic polymerase chain reaction (PCR) and reverse-transcribed
(RT)-PCR analysis
For genomic PCR analysis, 2 Wg of genomic DNA from each of the
respective cell lines was used. For RT-PCR analysis, the RNeasy1
Kit (Qiagen) and Superscript1 Kit (Gibco-BRL) were used to extract
the total RNA and to do the reverse transcription. The primers used
in these genomic PCR and RT-PCR experiments were EBNA1-454S
(sense: 5P-GGATCCATGGGTGATGGAGGCAGG-3P) and EBN-
A1-CAS (antisense: 5P-AAGATATCACTCCTGCCCTTC-3P).
2.7. Indirect immuno£uorescence analysis
Due to the low level of expression of EBNA1, an indirect immu-
no£uorescence analysis technique was used to detect the EBNA1 pro-
tein. Brie£y, cells were cultured on poly-L-lysine-coated cover-slips
overnight and then ¢xed with 3% paraformaldehyde in PBS for 15
min at room temperature. After thorough washing with phosphate
bu¡ered saline (PBS), cells were incubated with 1% Triton X-100 at
room temperature for 15 min in PBS. Then, the cells were incubated
with mouse anti-EBNA1 mAb (1:10 v/v in PBS; Chemicon,
MAB8173) at 37‡C for 1 h. The cells were then washed again in
PBS, and incubated with a⁄nity-puri¢ed goat anti-mouse IgG
(1:1000 v/v in PBS; Calbiochem, Germany) at 37‡C for 45 min.
Then, the cells were incubated in the dark with anti-goat £uorescein
isothiocyanate (FITC)-conjugated antibody (1:200 v/v, Santa Cruz
Biotechnology) at 37‡C for 45 min. Unbound antibodies were re-
moved by washing with PBS, after which the cells were further incu-
bated with propidium iodide (10 WM) and RNase A (50 Wg/ml) at
37‡C for 45 min. Both types of cells were visualized and photographed
using a standard £uorescence microscope (Axiophot, Zeiss, Ger-
many).
2.8. Western blot analysis and growth rate analysis by MTT assay
To observe the change of the p185HER2=neu protein expression level
in parental and di¡erent EBNA1 stable lines, Western blot analysis
was performed as described in [4]. In addition, the growth rates of
parental, wild-type and mutant EBNA1 stable lines were analyzed by
MTT assay as described in [4].
2.9. Anchorage independence assay
A soft agarose growth assay was carried out as follows: Brie£y, the
wild-type and mutant EBNA1 lines and their parental ip1 cells
(1U103 cells/well) were plated in 24-well plates in culture medium
containing 0.35% agarose (Gibco-BRL, Gaithersburg, MD, USA)
overlying a 0.7% agarose layer. The cells were then incubated at
37‡C for 3^4 weeks, after which the plates were stained with p-iodo-
nitrotetrazolium violet (1 mg/ml) overnight at 37‡C. Colonies greater
than 100 Wm in diameter were counted for each dish. Each soft aga-
rose assay was performed in triplicate.
2.10. Animals and tumorigenicity assay
4^6-week old female pathogen-free Balb/cAnNCrj-nu/nu athymic
nude mice, obtained originally from Charles River Laboratory (Yo-
kohama, Kanagawa, Japan), were bred in the Animal Center of the
National Defense Medical Center, Taipei, Taiwan, ROC. The care
and use of the animals were in accordance with institutional guide-
lines. For the tumorigenicity assay, the wild-type and mutant EBNA1
transfectants and the control ip1 cells in log-phase growth were trypsi-
nized, washed twice with PBS and centrifuged at 1500Ug. The viable
cells were counted, and 1.2U106 viable cells in 0.3 ml of serum-free
medium were injected s.c. into the right £anks of female homozygous
nu/nu mice under aseptic conditions. Tumor volumes were estimated
as the product of three-dimensional caliper measurements (longest
surface length and width; tumor thickness). The growth of tumors
was monitored once a week.
3. Results
3.1. Transcriptional and dose-dependent repression of neu
promoter by EBNA1
Repression of the neu promoter by EBNA1 was dose-de-
pendent (Fig. 1A, lanes 2^4). However, the pCEP4-AvrII, a
frame-shift mutant of the EBNA1 gene in pCEP4, had no
e¡ect on CAT activity (Fig. 1A, lane 5). It appears that the
pCEP4 plasmid, which contains the EBNA1 gene, has an
e⁄cient repression e¡ect on neu gene expression (Fig. 1A).
Therefore, the pCEP4 plasmid was used for further analysis.
To further study the interactions of EBNA1 gene products
with the neu promoter, we subcloned the EBNA1 from
pCEP4 plasmid into the expressing plasmid vector pcDNA3
resulting in the pcDNA3-EBNA1 recombinant construct. A
frame-shift mutant of pcDNA3-EBNA1, named pcDNA3-
EBNA1-AvrII, was also constructed and used as a negative
control. Increasing amounts of pcDNA3-EBNA1 were co-
transfected with pNeuEcoRVCAT (Fig. 1B,C, lanes 2^4). In-
hibition of the gene expression directed by the neu promoter
ip1-EBNA1-W30        ip1-EBNA1-WL5
SKOV3-ip1               ip1-EBNA1-C1          ip1-EBNA1-M1
Fig. 3. Morphology change of SKOV3.ip1 cells after being stably transfected with EBNA1. A: SKOV3.ip1 cells. B: ip1-EBNA1-C1 cells.
C: ip1-EBNA1-M1 cells. D: ip1-EBNA1-W30. E: ip1-EBNA1-WL5 cells. Panels A^E, 200U magni¢cation.
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was dependent on pcDNA3-EBNA1 concentration, with
around 50% repression observed at a pcDNA3-EBNA1:p-
NeuEcoRVCAT ratio of 1:1 (Fig. 1B,C, lanes 1^4). No inhi-
bition was observed in the presence of the pcDNA3-EBNA1-
AvrII mutant (Fig. 1B,C, lane 5). The repression e¡ect of
pcDNA3-EBNA1 is speci¢cally on the neu promoter and
there is no e¡ect on other promoters such as the RSV pro-
moter (compare lanes 3, 6 and 7 in Fig. 1B,C).
3.2. Inhibited expression of HER2/neu-encoded p185 in
EBNA1-expressing ovarian carcinoma transfectants
To see the in vivo e¡ect of EBNA1 on HER2/neu gene
expression, in this study we used the EBNA1-expressing stable
transfectants ip1-EBNA1-WL5 and ip1-EBNA1-W30, and the
vector-only (ip1-EBNA1-C1) and EBNA1 frame-shift control
lines (ip1-EBNA1-M1 and -M4). To ensure that the exoge-
nous EBNA1 gene had integrated into the genome of the
transfectants, genomic PCR analysis was performed. Fig. 2A
shows the results of genomic PCR analysis for the parental
ip1 cell line and two representative stable transfectants, ip1-
EBNA1-W30 and ip1-EBNA1-M1. As expected, the parental
ip1 cells did not contain any EBNA1 sequence, whereas the
two EBNA1 transfectants had acquired the transfected
EBNA1 DNA. The size of the major band (578 bp) was con-
sistent with the length of the designed sequence of the EBNA1
clone (Fig. 2A). Moreover, using RT-PCR EBNA1 mRNA
was detected in the ip1-EBNA1-W30 stable lines but not in
the parental ip1 cells or the two control lines ip1-EBNA1-C1
and ip1-EBNA1-M1 (Fig. 2B). PI staining and immuno£uo-
rescence further showed that the expression of EBNA1 pro-
tein was co-localized with the nucleus in the ip1-EBNA1-W30
and -WL5 lines, but not in the parental ip1 and mutant ip1-
EBNA1-M1 lines (Fig. 2C), indicating that EBNA1 protein
was indeed expressed in the nucleus. To examine whether
expression of EBNA1 in ip1-EBNA1 stable transfectants
can inhibit HER2/neu expression, immunoblot analysis for
the HER2/neu-encoded p185 protein was performed. The
p185 proteins were dramatically reduced in both the
EBNA1 transfectants (Fig. 2D, lanes 4 and 5), but not in
the vector control or the mutant (Fig. 2D, lanes 2 and 3).
3.3. EBNA1 expression in EBNA1 transfectants can suppress
the transformed phenotypes induced by HER2/neu
To determine the e¡ect of EBNA1 expression on the trans-
forming ability of HER2/neu-transformed SKOV3.ip1 cells,
the two EBNA1 transfectants ip1-EBNA1-W30 and -WL5,
the parental ip1 cells, and the ip1-EBNA1-C1 and -M1 con-
trol lines were assayed for some of the known transforming
parameters. The biological e¡ects of EBNA1 expression on
HER2/neu-transformed cells were ¢rst examined in culture.
The highly transformed morphology of parental ip1 cells
and the two control lines, ip1-EBNA1-C1 and -M1, was es-
sentially unchanged. These cells were rounded, piled up and
did not exhibit contact inhibition (Fig. 3A^C). However, the
highly transformed morphology of the ip1 cells was markedly
altered by EBNA1 transfection (Fig. 3D,E). The EBNA1-
transfectants, ip1-EBNA1-W30 and -WL5, exhibit a non-
transformed, £attened morphology and a contact-inhibited
growth pattern. These results indicate that EBNA1 gene prod-
ucts can speci¢cally reverse the transformed morphology of
HER2/neu-transformed ip1 cells.
3.4. In vitro suppression of SKOV3.ip1 cell transformation by
EBNA1 expression
The EBNA1-expressing SKOV3.ip1 lines were used to ex-
amine the e¡ect of EBNA1 expression on the HER2/neu over-
expressing ovarian cancer cells in vitro, by assaying growth
properties and colony formation in soft agarose. The growth
curves of the EBNA1-expressing ip1-EBNA1-W30 and -WL5
lines and the three control lines indicated that EBNA1 expres-
sion markedly reduced the growth rate of these ovarian cancer
cells in 0.1% FBS media, but slightly in 10% FBS media (Fig.
4A,B). To test the in£uence of the EBNA1 proteins on an-
chorage-independent growth, which is a good indicator of
transforming ability, all the control lines and the EBNA1
stable lines were assayed for their ability to grow in soft aga-
rose. Fig. 5 shows that the HER2/neu-overexpressing ip1 cells
and the ip1-EBNA1-C1 and -M1 lines exhibited high e⁄-
ciency in forming soft agarose colonies, whereas the colony-
forming e⁄ciencies of the ip1-EBNA1-W30 and -WL5 lines
were strikingly reduced. These data suggest that EBNA1 pro-
teins can suppress the transforming e¡ect of the HER2/neu
overexpression in ovarian cancer cells and inhibit cell growth
and anchorage-independent growth.
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Fig. 4. Growth rate analysis of parental and EBNA1 stably trans-
fected SKOV3.ip1 cells. Results of the MTT metabolic assay after
plating 1U104 cells into microtiter plates with (A) 10% FBS/
DMEM, (B) 0.1% FBS/DMEM. Triplicate experiments were run for
each cell line.
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3.5. EBNA1 as a tumor suppressor gene for HER2/neu-
overexpressing human ovarian carcinoma SKOV3.ip1 cells
A critical test for EBNA1-mediated transformation sup-
pression in ovarian cancer cells is the ability of EBNA1 to
suppress tumor formation in vivo. Therefore, a tumorigenicity
assay was performed by s.c. injecting nu/nu mice with 1.2U106
cells from the parental ip1 line and from either the two ip1-
EBNA1 stable lines or the two control lines, ip1-EBNA1-C1
and ip1-EBNA1-M1 (Fig. 6). Injections of the parental SKO-
V3.ip1 and the control ip1-EBNA1-C1 cells produced tumors
earlier than the ip1-EBNA1-transfectant lines and the tumor
burdens were very large at 4656U 2061 mm3 and 4861U 1392
mm3, respectively, by 70 days post-injection. Injections of the
ip1-EBNA1-M1 cells produced tumors a little later than the
parental ip1 and ip1-EBNA1-C1 injections, but 70 days after
injection the tumor burdens were still large at 3372U 1065
mm3. By contrast, the tumor-suppressing function of
EBNA1 was dramatic. Injections of the ip1-EBNA1-W30
and -WL5 cells did not produce tumors even at 70 days
post-injection, thus clearly demonstrating that EBNA1 can
suppress the tumorigenic potential of the ovarian carcinoma
SKOV3.ip1 cells.
4. Discussion
Overexpression of the HER2/neu gene is correlated with
enhanced tumorigenicity, enhanced metastatic potential, and
poor patient prognosis in many types of cancer [27,28]. In this
report, we have demonstrated that the EBNA1 gene product
can repress HER2/neu gene expression at the transcriptional
level by targeting the HER2/neu gene promoter (Fig. 1).
Therefore, it is likely that the reduced p185HER2=neu expression
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Fig. 5. Soft-agarose colony formation assay of parental and EBNA1 stably transfected SKOV3.ip1 cells. Parental and EBNA1 stably trans-
fected ip1 cells (1U103 cells/well) were plated in 24-well plates. A: a, parental ip1 cells ; b, ip1-EBNA1-C1 cells; c, ip1-EBNA1-M1 cells; d, ip1-
EBNA1-W30 cells; e, ip1-EBNA1-WL5 cells. B: Colonies greater than 100 Wm in diameter were counted for each dish. Triplicate experiments
were run for each cell line. Error bars indicate the standard deviation of number of colonies/well.
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in the ip1-EBNA1-expressing cell lines (Fig. 2) is due to tran-
scriptional repression of the overexpressed HER2/neu gene.
We have also shown that the EBNA1 can act as a transfor-
mation suppressor in HER2/neu-overexpressing human cancer
cells in vitro (Figs. 3^5), and reduce tumorigenicity in vivo
(Fig. 6). These results indicate that the EBNA1 gene can
function as a tumor suppressor gene for HER2/neu-overex-
pressing human cancer cells.
It has been reported previously that two viral oncoproteins,
adenovirus-5 E1a gene product (Ad-5 E1A) and SV40 large T
antigen (SV40LT), can repress the HER2/neu oncogene ex-
pression [7^9,29]. Here we report a third viral oncoprotein,
EBNA1, that can also act as a transforming suppressor of the
HER2/neu oncogene. It has been shown that the repression of
the HER2/neu gene by Ad-5 E1A and SV40LT is mediated by
interacting with the transcriptional co-activator p300 [30,31].
However, the mechanism of the repression of the HER2/neu
gene by EBNA1 remains to be investigated. At present,
EBNA1 is known to be involved in a variety of cellular func-
tions, including DNA-binding [32], RNA-binding [19], nuclear
localization [33], and transcriptional activation [34]. Since
EBNA1 is structurally and functionally di¡erent from Ad-5
E1A and SV40LT, then EBNA1 must presumably repress
HER2/neu oncogene expression via a distinct pathway. We
speculate that the repression of HER2/neu by EBNA1 may
be mediated by an indirect protein^protein interaction mech-
anism because no EBNA1-speci¢c binding sequences are
found on the HER2/neu promoter element. Evolutionarily, it
will be of interest to know why certain viral oncoproteins,
such as Ad-5 E1A, SV40LT and EBNA1, have a suppressing
e¡ect on oncogenic transformation.
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